News|Podcasts|March 12, 2026

Moving CAR-T Beyond Oncology

Author(s)Mike Hollan, Vincent Hennemand

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Sail Biomedicine’s chief products and operations officer joined the Pharmaceutical Executive Podcast to discuss how researchers are developing CAR-T therapies that go beyond oncology. According to him, recent advancements have provided researchers with significant results using CAR-T to treat autoimmune conditions, such as lupus or rheumatoid arthritis.

Hennemand explains the historical context of cell-based therapies in oncology, noting their success but limitations due to high costs and logistical challenges.
Hennemand explains that Sail started in oncology but quickly pivoted to autoimmune disorders due to the suitability of RNA-based CAR T therapies.
Hennemand highlights the advantages of RNA technology, such as quick expression and fast repopulation, which make it ideal for autoimmune disorders.
Hennemand mentions that Sail’s closest competitors also started in oncology but have since shifted their focus to autoimmune disorders.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

November 2nd, 2026

Pharmaceutical Executive Daily: FDA Approves Voceryq

FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.

November 2nd, 2026

States Take Center Stage in the Drug Pricing Fight

PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.

October 26th, 2026

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

October 26th, 2026

The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki

Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

October 23rd, 2026

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.

October 23rd, 2026

Building Biopharma Manufacturing for Speed, Scale, and Flexibility

Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

Moving CAR-T Beyond Oncology

Related to this article

Trending on PharmExec

What is it Like to Go From Treating Patients Directly to Running a Company?

FDA Grants Accelerated Approval to INOVIO’s Voceryq for RRP, Reducing Surgical Burden

States Take Center Stage in the Drug Pricing Fight

Pharmaceutical Executive Daily: FDA Approves Voceryq

What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?